CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has obtained approval for a CE mark label expansion extending the time within which plasma can be treated with the INTERCEPT Blood System to 20 hours after collection. The prior approved label claim allowed INTERCEPT treatment only within 8 hours of blood collection. This new extended treatment window applies to plasma from single donor apheresis and pooled whole blood collections.
